Pilot study using the ECHO model to enhance linkage to care for patients with hepatitis C in the custodial setting.
antiviral therapy
barriers
prison
viral infection
Journal
Journal of viral hepatitis
ISSN: 1365-2893
Titre abrégé: J Viral Hepat
Pays: England
ID NLM: 9435672
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
11
06
2020
revised:
10
08
2020
accepted:
11
08
2020
pubmed:
20
8
2020
medline:
1
9
2021
entrez:
20
8
2020
Statut:
ppublish
Résumé
Prisoners in most countries have a higher prevalence of HCV than the general population, but their access to treatment is very limited. Our aim was to evaluate a pilot programme using the ECHO model to enhance linkage to care in patients with HCV in 3 Argentinean prisons between October 2018 and January 2020. All inmates were invited to participate, and data were collected through a personal interview. We then estimated HCV prevalence with dried blood spot and performed a logistic regression analysis to identify risk behaviours associated with HCV infection. Finally, HCV management was assessed and monitored through ECHO. Overall, 1141 inmates agreed to participate, representing 39.7% of the total prison population. Anti-HCV prevalence was estimated at 1.58% (CI 0.93; 2.48), being significantly higher in women 2.98% (CI 1.4;5.6) than in men 1.07% (CI 0.5; 2.0); P = .03. Patients with anti-HCV were significantly older than those who tested negative, 42.3 years (CI 37.6;47.1) vs 30.1 years (CI 30.6;31.2), P < .001, respectively. Multiple logistic regression analysis, identified age OR 1.07 (CI 1.03;1.12, P = .001), history of sexually transmitted disease OR 3.08 (CI 0.97;9.82, P = .057) and intravenous drug use OR 12.6 (CI 3.31;48.53, P < .001) as risk factors associated with anti-HCV. Treatment was initiated in all the patients with specialist physician support utilizing ECHO model. In conclusion, our pilot study reported a low prevalence of anti-HCV in the studied population. Incarceration provides an ideal opportunity for testing and treating HCV. ECHO model arises as a useful tool to support assessment and treatment for inmates with chronic HCV.
Substances chimiques
Hepatitis C Antibodies
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1430-1436Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
World Health Organization. Global Hepatitis report. 2017. Available from: http://www.who.int/publications/global-hepatitis-report2017/en/. Accessed December 11, 2019.
Lazarus JV, Safreed-Harmon K, Thursz MR, et al. The Micro-elimination approach to eliminating hepatitis C: strategic and operational considerations. Semin Liver Dis. 2018;38(3):181-192.
Alonso M, Gutzman A, Mazin R, Pinzon CE, Reveiz L, Ghidinelli M. Hepatitis C in key populations in Latin America and the Caribbean: systematic review and meta-analysis. Int J Public Health. 2015;60(7):789-798.
Dolan K, Wirtz AL, Moazen B, et al. Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees. Lancet. 2016;388(10049):1089-1102.
Zampino R, Coppola N, Di Caprio G, Sagnelli C, Sagnelli E. Hepatitis C virus infection and prisoners: Epidemiology, outcome and treatment. World J Hepatol. 2015;7(21):2323-2330.
Dirección de SIDA y ETS. Ministerio de Salud de la Nación. Estudio de prevalencia de VIH, sífilis, hepatitis virales y tuberculosis en personas en contextos de encierro en unidades del Servicio Penitenciario Federal. http://www.msal.gob.ar/images/stories/bes/graficos/0000001084cnt-2017-12-29_carceles-vih.pdf. Published 2017. Accessed December 11, 2019.
Post JJ, Arain A, Lloyd AR. Enhancing assessment and treatment of hepatitis C in the custodial setting. Clin Infect Dis. 2013;57(Suppl 2):70-74.
Khaw FM, Stobbart L, Murtagh MJ. “I just keep thinking I haven’t got it because I’m not yellow”: A qualitative study of the factors that influence the uptake of Hepatitis C testing by prisoners. BMC Public Health. 2007;7:98.
Lloyd AR, Clegg J, Lange J, et al. Safety and effectiveness of a nurse-led outreach program for assessment and treatment of chronic hepatitis c in the custodial setting. Clin Infect Dis. 2013;56(8):1078-1084.
Cuadrado A, Llerena S, Cobo C, et al. Microenvironment eradication of hepatitis C: a novel treatment paradigm. Am J Gastroenterol. 2018;113(11):1639-1648.
Mendizabal M, Ridruejo E, Ceballos S, et al. The ECHO model proved to be a useful tool to increase clinicians’ self-effectiveness for care of patients with Hepatitis C in Argentina. J Viral Hepat. 2019;26(11):1284-1292.
EASL-ALEH clinical practice guidelines: non invasive tests for evaluation of liver severity and prognosis. J Hepatol. 2015;63:237-264.
Ridruejo E, Galdame O.Recomendaciones para el Tratamiento de la Hepatitis C Crónica por Virus C Indicaciones de Tratamiento; 2018. https://www.aaeeh.org.ar/images/CONSENSOSYGUIAS/Guias-XX18--ltima.pdf. Accessed December 11, 2019.
Von EE, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE ) statement : guidelines for reporting observational studies. Lancet. 2007;370:1453-1457.
Polaris Observatory. https://cdafound.org/dashboard/polaris/dashboard.html. Accessed April 26, 2020.
Semaille C, Le Strat Y, Chiron E, et al. Prevalence of human immunodeficiency virus and hepatitis C virus among French prison inmates in 2010: a challenge for public health policy. Euro Surveill. 2013;18(28):1-7.
Fazel S, Baillargeon J. The health of prisoners. Lancet. 2011;377(9769):956-965.
Liu S, Watcha D, Holodniy M, Goldhaber-Fiebert JD. Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: A cost-effectiveness analysis. Ann Intern Med. 2014;161(8):546-553.
Marco A, Esteban JI, Solé C, et al. Hepatitis C virus reinfection among prisoners with sustained virological response after treatment for chronic hepatitis C. J Hepatol. 2013;59(1):45-51.
Stone J, Fraser H, Lim AG, et al. Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis. Lancet Infect Dis. 2018;18(12):1397-1409.
Solomon L, Flynn C, Muck K, Vertefeuille J. Prevalence of HIV, Syphilis, Hepatitis B, and Hepatitis C Among Entrants to Maryland Correctional Facilities. J Urban Health. 2004;81(1):25-37.
Thornton K, Sedillo ML, Kalishman S, Page K, Arora S. The new Mexico peer education project: Filling a critical gap in HCV prison education. J Health Care Poor Underserved. 2018;29(4):1544-1557.